Something went wrong with the connection!

Biliary Tract Cancers (BTCs) Drug Market, Market Insights and Treatment

 Breaking News
  • No posts were found

Biliary Tract Cancers (BTCs) Drug Market, Market Insights and Treatment

September 25
14:51 2020
Biliary Tract Cancers (BTCs) Drug Market, Market Insights and Treatment

(Albany, US) DelveInsight has launched a new report on Biliary Tract Cancers Market

 

DelveInsight’s “Biliary Tract Cancers (BTCs) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Biliary Tract Cancers (BTCs), historical and forecasted epidemiology as well as the Biliary Tract Cancers (BTCs) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The Biliary Tract Cancers (BTCs) market report provides current treatment practices, emerging drugs, Biliary Tract Cancers (BTCs) market share of the individual therapies, current and forecasted Biliary Tract Cancers (BTCs) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Biliary Tract Cancers (BTCs) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

 

Biliary Tract Cancer (BTC), also known as Cholangiocarcinoma (CCA) is a rare and heterogeneous malignant neoplasm with epithelial cell origin of biliary duct and histologic and biochemical features of cholangiocyte differentiation. The malignant tumor may arise from any portion of the bile duct i.e., from terminal ductules (canals of Hering) to the ampulla of Vater, as well as at the peribiliary glands (intramural and extramural) and sometimes may affect gall bladder. Inflammation, cholestasis and receptor tyrosine kinases such as IL-6 receptor, c-MET and the EGFR family members are key signaling pathways in cholangiocarcinogenesis. It can be classified anatomically based on tumor location within the biliary tree into intrahepatic (iCCA), perihilar (pCCA), and distal (dCCA) cholangiocarcinoma subtypes. The latter two subtypes were previously grouped as extrahepatic CCA (eCCA) but are now considered distinct entities based upon differences in their tumor biology and management. According to the ICD 10 classification

 

View free sample page:- https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-market

 

Biliary Tract Cancers Treatment

Till now, surgical treatments are the only potentially curative therapeutic options for all the subtypes of CCA. However, the majority of CCA patients are diagnosed at late stage disease, and nearly more than one-fourth of patients considered resectable are found to be unresectable during explorative laparotomy. Few more aggressive surgical approaches and improved radiologic techniques have resulted in improved R0 (tumor-free margins) resection rates but recurrence rates remain high.

 

Biliary Tract Cancers Market

Besides all these treatment options, the market consists of various unmet needs including lack of therapeutic treatment, poor understanding of molecular components involved in signaling pathways and lack of awareness. To counter the current unmet needs of the market and to provide better treatment options for CCA, various research studies have focused on developing therapeutic treatments for CCA. The launch of various multiple-stage pipeline products will significantly revolutionize the CCA market dynamics in the near future. The emerging drug analysis along with their detailed profiling is done by the Delveinsight. Among all these, Therapies with biomarkers IDH1/IDH2 mutations and FGFR translocations are found to be most promising.Besides all these treatment options, the market consists of various unmet needs including lack of therapeutic treatment, poor understanding of molecular components involved in signaling pathways and lack of awareness. To counter the current unmet needs of the market and to provide better treatment options for CCA, various research studies have focused on developing therapeutic treatments for CCA The launch of various multiple-stage pipeline products will significantly revolutionize the CCA market dynamics in the near future. The emerging drug analysis along with their detailed profiling is done by the Delveinsight. Among all these, Therapies with biomarkers IDH1/IDH2 mutations and FGFR translocations are found to be most promising.

 

Key players of the report

  • Agios Pharmaceuticals
  • Incyte Corporation

 

Biliary Tract Cancers Report Scope

  • The report covers the descriptive overview of Biliary Tract Cancers (BTCs), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Biliary Tract Cancers (BTCs) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Biliary Tract Cancers (BTCs) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Biliary Tract Cancers (BTCs) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Biliary Tract Cancers (BTCs) market

 

Download free sample page:-  https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-market

 

Table of content

1. Key Insights

2. Executive Summary of Biliary Tract Cancers (BTCs)

3. Competitive Intelligence Analysis for Biliary Tract Cancers (BTCs)

4. Biliary Tract Cancers (BTCs): Market Overview at a Glance

5. Biliary Tract Cancers (BTCs): Disease Background and Overview

6. Patient Journey

7. Biliary Tract Cancers (BTCs) Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Biliary Tract Cancers (BTCs) Treatment

11. Marketed Products

12. Emerging Therapies

13. Biliary Tract Cancers (BTCs): Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Biliary Tract Cancers (BTCs)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

Why should you buy this report?

  • The report will help in developing business strategies by understanding trends shaping and driving the Biliary Tract Cancers (BTCs) market
  • To understand the future market competition in the Biliary Tract Cancers (BTCs) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Biliary Tract Cancers (BTCs) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Biliary Tract Cancers (BTCs) market
  • To understand the future market competition in the Biliary Tract Cancers (BTCs) market

 

Related Reports

 

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Related Articles

Calendar

October 2020
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  

Categories